Breast Cancer World R&D Summit - BioGenex International

10 Feb

BioGenex is leading the miRNA revolution with the most advanced miRNA solutions and the broadest portfolio of miRNA- In Situ Hybridization (ISH) probes (>200), ISH detection system for FFPE tissue and affordable automation platforms. miRNA dysregulation has been associated with carcinogenesis and miRNA expression profiles are potential biomarker candidates for tumor diagnosis. With over 1.5 million new cancer cases per year, there is an urgent need for new solutions for tumor precision medicine. Using BioGenex’s miRNA system, it was found that the expression of miR-17, miR-21 and let-7a is down-regulated in BRCA-mutated breast carcinoma compared to wild –type breast carcinoma. 


Precision Breast Cancer World R&D Summit.jpg


The ability to predict mutation status may help more accurately determine patients suitable for BRCA genetic testing, which is both costly and time consuming. Furthermore, BioGenex system for characterization of cancer of unknown primary (CUP) and undifferentiated tumors is an unrivaled game changer. We believe that miRNA expression profiles have an immense potential to play a significant role in diagnosis, prognosis, characterization and therapy selection of undifferentiated malignancies.


Unlike PCR based techniques, where miRNA isolated from frozen or FFPE tissues is profiled but with questionable specificity, in situ hybridization system for miRNA has the ability to generate robust chromogenic signal while preserving the spatial context of the tissue sample. This provides a powerful tool for precise tumor characterization.


About miRNAs:

microRNAs [miRNAs], well conserved in eukaryotic organisms, are short, single stranded 20-22 nucleotide long non-coding RNA, which are cleaved from 70-130 nucleotide precursors. miRNAs are regulatory molecules and act as transcriptional and post-transcriptional regulators of gene expression. miRNAs exert their function via base pairing with complementary mRNA molecules, resulting in gene silencing via transcriptional repression or target degradation.


About Us:

BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.


Read more on the Precision Breast Cancer summit website

Latest News